Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

AnaptysBio, Inc. Common Stock (ANAB)
AnaptysBio, Inc. Common Stock
XNAS:ANAB
41.99
-0.40%

Ask
$54.10 - 100.00
Bid
$37.96 - 100.00
Low
$41.52
High
$42.66
Open
$42.66
Prev Close
$42.16
52W High
43.31
52W Low
12.21
Volume
229745
Avg Vol (3m)
682277.4
Float
26040258.97
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2834
Sector: Health Technology
Industry: Biotechnology
Date Listed: 01/26/2017
Primary Exchange: XNAS

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Phone: 858-362-6295
Address: 10770 Wateridge Circle, Suite 210
City: San Diego
State: CA
Postal Code: 92121
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
136
P/E (TTM)
-14.780000
P/B (TTM)
-39.043500
EPS
0.52
Round Lot
100
Composit FIGI
BBG0026ZDHR0
Share Class FIGI
BBG0026ZDHT8
Share Class Shares Outstanding
28.00M
Weighted Shares Outstanding
27.69M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own ANAB. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.